JFG
BBIO icon

Jefferies Financial Group’s BridgeBio Pharma BBIO Stock Holding History

Jefferies Financial Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,500
Closed -$77.3K – 1417
2024
Q1 		$77.3K Buy
+2,500
New +$85K ﹤0.01% 1466

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's BBIO Position: Q1 2026 in Review

Jefferies Financial Group reduced its BridgeBio Pharma (BBIO) stake by 59% in Q1 2026, selling an estimated $8.53M and leaving 82,300 shares worth $6.11M. The position accounts for 0.04% of the portfolio, ranked #300.

Jefferies Financial Group first reported a position in BBIO in Q1 2023 and has held it in 8 quarters since. The position peaked at $15.3M in Q4 2025. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Jefferies Financial Group held 82,300 shares of BridgeBio Pharma worth $6.11M as of Q1 2026.
  • Jefferies Financial Group sold 117,700 BridgeBio Pharma shares in Q1 2026, an estimated $8.53M.
  • BridgeBio Pharma made up 0.04% of Jefferies Financial Group's portfolio in Q1 2026, its #300 holding.
  • Jefferies Financial Group first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 8 quarters since.
  • Jefferies Financial Group's BridgeBio Pharma position peaked at $15.3M in Q4 2025.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.